ReviewiScience2026
MicroRNAs as master regulators of macrophage function in atherosclerosis: From polarization to therapeutic potential.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis, a chronic inflammatory disease characterized by lipid accumulation, plaque formation, and calcification within large arteries, remains a leading cause of cardiovascular morbidity. This review integrates emerging evidence on the central role of microRNAs (miRNAs) as master regulators of macrophage biology in atherosclerosis pathogenesis. We highlight how miRNAs orchestrate macrophage polarization (e.g., miR-155 promotes the proinflammatory M1 phenotype; miR-126 facilitates the anti-inflammatory M2 phenotype), inflammatory responses (via NF-κB/TLR signaling), lipid metabolism (through the modulation of CD36 and ABCA1/ABCG1-mediated uptake/efflux), and programmed cell death (through apoptosis, autophagy, and ferroptosis). Therapeutically, targeting miRNA-mediated regulatory networks in macrophages offers unique potential to concomitantly ameliorate lipid accumulation, inflammation, and plaque vulnerability. However, translational challenges-including tissue-specific delivery, miRNA stability, and clinical validation-require innovative solutions such as engineered nanoparticles and combinatorial strategies. Advancing miRNA-based therapeutics may lead to the development of precision interventions for atherosclerosis beyond conventional approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.